16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors
Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach
Read more at globenewswire.comSkye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
SKYE BIOSCIENCE INC
NASDAQ:SKYE (2/11/2025, 8:00:01 PM)
Premarket: 2.65 -0.24 (-8.3%)2.89
-0.54 (-15.74%)
SKYE Latest News and Analysis
14 hours ago - ChartmillTuesday's session: top gainers and losersIntrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
